Ann: ISLA-101 Phase 2a clinical trial update, page-6

@ma420 No surprise, IMHO this is a slow burn and we'll have to wait until middle next year for this stock to shine.

The stars are slowly aligning:

1) IPO subscribers & impatient holders have cleared their positions. Bottom reached?
2) Signs of accumulation by at least one heavyweight investor
3) Confirmation of phase II going forward H2 next year
4) Drug is mature; Phase IIa should be relatively straight forward
5) Little cash burn
6) Quiet confidence from management; they're getting up to speed; maybe they have some more cards up their sleeves?

So far, I have only a modest ILA parcel (~$10K) but intend to buy a lot more next year subject to how my favourite biotech performs